Tag Archive for: Interim results

Hansa Biopharma to host Q3 2026 interim results conference call

Lund, Sweden, October 28, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – September 2026 on November 11, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Adam […]

Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025

Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more…

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024

Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track […]

Futura Medical plc – Interim Results 2023

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, is pleased to announce its unaudited interim results for the six months ended 30 June 2023 (“H1 2023”). MED3000, under the brand name Eroxon®, is the first pan-European clinically proven topical treatment for Erectile Dysfunction (“ED”) available without the need of a doctor’s prescription […]

Poolbeg Pharma plc – Interim results for the six months to 30 June 2023

Significant progress made and well positioned for future growth  13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023. Read more…

© Optimum Strategic Communications.